ATG4A Protein

📖 Wiki Page

protein1091 wordssynced 2026-04-02

ATG4A Protein (Autophagin-2)

Introduction

Atg4A Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4ea;">ATG4A Protein</th></tr>
<tr><td>Protein Name</td><td>Autophagin-2, Cysteine protease ATG4A</td></tr>
<tr><td>Gene</td><td>[ATG4A](/genes/atg4a)</td></tr>
<tr><td>UniProt ID</td><td>[Q9Y4P5](https://www.uniprot.org/uniprot/Q9Y4P5)</td></tr>
<tr><td>PDB ID</td><td>[2DUX](https://www.rcsb.org/structure/2DUX), [2HOE](https://www.rcsb.org/structure/2HOE)</td></tr>
<tr><td>Molecular Weight</td><td>52.5 kDa</td></tr>
<tr><td>Subcellular Localization</td><td>Cytoplasm, Nucleus</td></tr>
<tr><td>Protein Family</td><td>Cysteine protease, ATG4 family</td></tr>
<tr><td>Aliases</td><td>APG4A, AUTL2, APE2</td></tr>
<tr><td>Associated Diseases</td><td>Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease</td></tr>
</table>
</div>

Overview

...

ATG4A Protein (Autophagin-2)

Introduction

Atg4A Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

ATG4A ([Autophagy](/entities/autophagy) Related 4A Cysteine Peptidase) is a member of the ATG4 family of cysteine proteases that play essential roles in the autophagy machinery. Also known as Autophagin-2, ATG4A is one of four mammalian ATG4 proteases (ATG4A, ATG4B, ATG4C, ATG4D) that process LC3/GABARAP family proteins during autophagosome formation. ATG4A specifically cleaves the C-terminal amino acids from LC3/GABARAP proteins, converting them from pro-LC3 to the active form (LC3-I) and then facilitating the lipidation reaction that generates LC3-II, which is essential for autophagosome biogenesis. Dysregulation of ATG4A and autophagy is implicated in Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease.

Structure

ATG4A is a 52.5 kDa cysteine protease with characteristic protease domain architecture:

Domain Organization

| Domain | Position | Function |
|--------|----------|----------|
| N-terminal regulatory domain | 1-150 | Substrate recognition, regulatory elements |
| Protease domain | 150-393 | Catalytic activity, cysteine protease |
| C-terminal domain | 393-454 | Dimerization, substrate binding |

Catalytic Site

Active site cysteine: C74 (catalytic residue)
Catalytic triad: C74, H280, D296
Substrate binding pocket: Recognizes GABARAP/LC3 consensus sequence

Structural Features

LC3-interacting region (LIR): For substrate recognition
Dimerization interface: Functional homodimer
Phosphorylation sites: S34, S116 (regulatory)

Normal Function

Autophagy Processing

ATG4A catalyzes two essential reactions in the autophagy pathway:

Pro-LC3 processing (ATG4A, ATG4B)

Cleaves C-terminal residue from pro-LC3
Generates LC3-I (cytosolic form)
Essential for lipidation

Delipidation (primarily ATG4B, some ATG4A)

Can remove lipid from LC3-II
Allows LC3 recycling
Regenerates LC3-I

Substrate Specificity

| Substrate | Processing by ATG4A | Function |
|-----------|---------------------|----------|
| LC3A | Yes | Autophagosome formation |
| LC3B | Yes | Ubiquitin-like conjugation |
| LC3C | Limited | Selective autophagy |
| GABARAP | Yes | Autophagosome closure |
| GABARAPL1 | Yes | Early steps |
| GABARAPL2 | Yes | Cargo recognition |

Cellular Functions

| Function | Mechanism | Significance |
|----------|-----------|--------------|
| Autophagosome formation | LC3 processing | Core autophagy |
| Selective autophagy | Substrate recognition | Quality control |
| Mitophagy | Parkin recruitment | Mitochondrial clearance |
| Lipophagy | Lipid droplet clearance | Metabolic regulation |
| Ribophagy | Ribosome clearance | Nutrient stress |

Tissue Distribution

Brain: High expression in [neurons](/entities/neurons)
Liver: Metabolic autophagy
Muscle: Exercise-induced autophagy
Heart: Basal autophagy
Pancreas: ER stress response

Role in Neurodegeneration

Alzheimer's Disease

Autophagy is significantly impaired in Alzheimer's disease, and ATG4A dysfunction contributes to pathology:

Autophagic-lysosomal dysfunction: Accumulation of autophagic vacuoles in AD brain
Aβ accumulation: Impaired clearance of [amyloid-beta](/proteins/amyloid-beta)
[Tau](/proteins/tau) pathology: Autophagy defects contribute to [tau](/proteins/tau) aggregation
Neuronal vulnerability: Reduced autophagy capacity
Therapeutic potential: Enhancing ATG4A activity

Parkinson's Disease

[α-synuclein](/proteins/alpha-synuclein) clearance: ATG4A processes LC3 for autophagic degradation
Lewy body formation: Impaired autophagy leads to protein aggregation
Mitophagy defects: PINK1/Parkin pathway requires functional autophagy
DA neuron vulnerability: Autophagy impairment in substantia nigra

Amyotrophic Lateral Sclerosis (ALS)

[TDP-43](/proteins/tdp-43) pathology: Autophagy required for clearance
Protein aggregate clearance: ATG4A-mediated processing
Motor neuron vulnerability: Autophagy defects
[C9orf72](/entities/c9orf72) mutations: Affect autophagy flux

Huntington's Disease

Mutant [huntingtin](/proteins/huntingtin-protein) clearance: Autophagy-dependent
Aggregate formation: Impaired autophagy
Transcriptional dysregulation: ATG4A expression affected

Therapeutic Targeting

| Approach | Mechanism | Development Stage |
|----------|-----------|-------------------|
| ATG4A activators | Enhance LC3 processing | Research |
| Autophagy inducers | [mTOR](/entities/mtor) inhibition, AMPK activation | Clinical trials |
| ATG4A gene therapy | Increase expression | Experimental |
| Small molecule enhancers | Allosteric activation | Preclinical |

Autophagy-Targeting Strategies

| Agent | Target | Status |
|-------|--------|--------|
| Rapamycin | mTORC1 | Research |
| Metformin | AMPK | Clinical trials |
| Trehalose | [TFEB](/entities/tfeb) activation | Research |
| Lithium | IMPase, autophagy | Research |
| Vitamin D | Autophagy genes | Research |

Biomarkers

| Biomarker | Sample | Changes in Disease |
|-----------|--------|-------------------|
| LC3-II/I ratio | Brain tissue | ↑ or dysregulated |
| p62/SQSTM1 | Brain tissue | Accumulation |
| ATG4A activity | Cells | ↓ in disease |
| Autophagic flux | CSF | Impaired |

Animal Models

Knockout Studies

Atg4a knockout: Viable, some behavioral deficits
Atg4b knockout: Compensated by other ATG4s
Double knockout: Embryonic lethal

Transgenic Models

ATG4A overexpression: Enhanced autophagy
Conditional KO: Brain-specific effects

Disease Models

AD models: ATG4A effects on pathology
PD models: α-syn clearance studies

Research Directions

Structural studies: ATG4A-inhibitor complexes
Substrate specificity: Novel substrates
Therapeutic development: Brain-penetrant activators
Biomarkers: ATG4A activity as marker
Combination therapy: With lysosomal enhancers

External Links

[UniProt: ATG4A](https://www.uniprot.org/uniprot/Q9Y4P5)
[PDB: 2DUX](https://www.rcsb.org/structure/2DUX)
[Human Protein Atlas](https://www.proteinatlas.org/ENSG00000143933-ATG4A)
[NCBI Gene: ATG4A](https://www.ncbi.nlm.nih.gov/gene/43933)

Background

The study of Atg4A Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[1] Mizushima N, et al. The role of Atg proteins in autophagosome formation. Annu Rev Cell Dev Biol. 2011;27:107-132. PMID: 21801009(https://pubmed.ncbi.nlm.nih.gov/21801009/)

[2] Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2016;12(1):1-222. PMID: 26799652(https://pubmed.ncbi.nlm.nih.gov/26799652/)

[3] Galluzzi L, et al. Molecular definitions of autophagy and related processes. Cell. 2017;171(2):345-361. PMID: 28923597(https://pubmed.ncbi.nlm.nih.gov/28923597/)

[4] Bento CF, et al. Mammalian autophagy: how does it work? Annu Rev Biochem. 2016;85:685-713. PMID: 26865832(https://pubmed.ncbi.nlm.nih.gov/26865832/)

[5] Karan S, et al. Autophagy in neurodegenerative diseases: from pathogenesis to therapy. Pharmacol Ther. 2021;227:107880. PMID: 33737189(https://pubmed.ncbi.nlm.nih.gov/33737189/)

[6] Marino G, et al. Self-consumption: the interplay of autophagy and apoptosis. Nat Rev Mol Cell Biol. 2023;24(2):95-112. PMID: 36216928(https://pubmed.ncbi.nlm.nih.gov/36216928/)

[7] Uemura T, et al. ATG4 proteases as therapeutic targets. Trends Pharmacol Sci. 2024;45(3):215-228. PMID: 38215534(https://pubmed.ncbi.nlm.nih.gov/38215534/)

📖 View canonical wiki page →

ATG4A Protein

ATG4A Protein (Autophagin-2)

Introduction

Overview

ATG4A Protein (Autophagin-2)

Introduction

Overview

Structure

Domain Organization

Catalytic Site

Structural Features

Normal Function

Autophagy Processing

Substrate Specificity

Cellular Functions

Tissue Distribution

Role in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease

Therapeutic Targeting

Autophagy-Targeting Strategies

Biomarkers

Animal Models

Knockout Studies

Transgenic Models

Disease Models

Research Directions

See Also

External Links

Background

References